Array Biopharma, Inc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Array Biopharma, Inc

ARRY 9.490

+5.0%

Jan 6 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (284)	5/18/2014 7:51:41 PM
From: scaram(o)uche	of 321

We've been discussing: 1. the taflinar/mekinist (dabrafinib/trametinib) combo, and the relevance to arry of the proposed swap between Novartis and GSK, and 2. the Novartis trial combining MEK162 with the CDK4/6 inhibitor LEE011..... abstracts.asco.org What I didn't know is that GSK is collaborating with Pfizer (bidding for Astra, home of selumetinib) to launch a combo trial of MEK and CDK4/6 inhibitors (trametinib/palbociclib) of their own....... clinicaltrials.gov And the big news this week is that FDA has lubed an NDA for palbociclib, based on phase II data, to treat ER+ HER2- breast Ca. pfizer.com Dizzy, I don't know how to read them. But there are tea leaves scattered all over.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next